Clinical trial
Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity
NCT06041217 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 15, 2023
- Completion date
- May 7, 2025
- Enrollment
- 242 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.